were no published data concerning the liver toxicity of methotrexate in patients with rheumatoid arthritis, many rheumatologists initially followed the dermatology guidelines and obtained biopsy specimens before treatment and frequently thereafter. However, as the use of methotrexate increased, it emerged that clinically serious liver disease was less common in patients with rheumatoid arthritis than in those with psoriasis. The pendulum has consequently now swung to the other extreme, with rheumatologists infrequently performing liver biopsy-a practice that is further enforced by recently published guidelines from the American College of Rheumatology:2 on the basis of findings of a very low incidence of histological abnormalities in patients with rheumatoid arthritis who are taking methotrexate, surveillance liver biopsying is not recommended (table 2) . However, patients with a prior excessive alcohol consumption, persistently increased ab- There are a number of differences between patients with psoriasis only and those with psoriatic arthritis. Whilst it is possible to have severe skin involvement and no joint disease, it is rare to have severe joint disease without any skin disease, and generally there is a relationship between the severity of skin disease and the frequency of joint disease. Psoriatic arthritis is reported to be more commonly associated with pustular and erythrodermic psoriasis.9 There is convincing evidence of genetic (HLA) differences between Dsoriasis and Dsoriatic arthritis.'0 Hizh but whether there are differences in the amounts of alcohol consumed by patients with psoriasis compared with those with psoriatic arthritis is not known. There are significant differences between patients with psoriasis and those with psoriatic arthritis, but from the published studies it is difficult to assess whether the two categories of patients have the same frequency of liver histology abnormalities before and during methotrexate treatment. Most of the studies assessing the hepatic toxicity of methotrexate in patients with psoriasis have not given details of the frequency of psoriatic arthritis in their patients." Furthermore, different studies have used different methods for grading liver biopsy findings in patients receiving methotrexate, and it is difficult to compare findings between the studies.2 From the published studies it is therefore difficult in general to ascertain whether there is any significant difference between patients with psoriasis and those with psoriatic arthritis with regard to the hepatic toxicity of methotrexate (table 3) . There is a need for further studies to answer these questions.
While liver biopsying is generally a safe procedure, it can lead to serious complications such as subcapsular haemorrhage, intraperitoneal bleeding, gallbladder perforation, bile peritonitis, and pneumothorax. The overall risk associated with liver biopsying is approximately 1-5 in 1000 procedures and the mortality varies from 0% to 0-12%, with an average of O-03%.2 There are no published British data on the cost of the procedure, but in the US Problems with pain-is the messenger to blame?
The nature and definition of pain has troubled mankind since the earliest times. To the ancient Greeks, pleasure and pain were closely linked 'passions of the soul', such that the absence of one led inevitably to the other, and vice versa. 
